Pfizer’s US Rituximab Launched At A 24% Discount
Trastuzumab Will Launch Next Month With A 22% Lower Price
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
Pfizer has received a positive opinion from the CHMP recommending granting a pan-European marketing authorization for its Ruxience rituximab biosimilar version of MabThera. At the same time, CHMP nods for hybrid medicines were received by SciPharm and Teva, while Mylan, Betapharm and Accord saw generics endorsed by the committee.